Anavex Life Sciences Corp (AVXL)

[blu_1]

On slide 16, 5 cognitive domains were listed from the cdr battery which are most pertinent to assessing/diagnosing MCI-AD. The first four of them seem to have been addressed in this presentation (word and pic recognition were bundled into calculation of the Quality of Episodic Memory score). Was numeric working memory addressed? Slide 20 includes Digit Vigilance Reaction Time. Is that part of numeric working memory?

Overall, I think results were impressive, especially considering the trial was affected by a pandemic and PDD was never even on Anavex's agenda as a target indication. They just explored it b/c the Michael J. Fox Foundation wanted them to and would help foot the bill. The presentation had to be brief, so anavex just focused on the most pertinent data from this Parkinson's trial related to MCI-Alzheimer's. Remember, the trial wasn't even an Alzheimer's trial and the patients didn't even have Alzheimer's. CTAD is an Alzheimer's conference. Data presented included both doses (the 30mg cohort is always a drag) and did not select for subjects w/WT Sigmar 1 and COMT genes. Precision medicine is the cornerstone of Anavex's strategy, and that wasn't even applied! AVXL's critics *conveniently* fail to mention all of the above.